Self-insured employers are considering investing in GLP-1 drugs for weight loss to address rising healthcare costs. These drugs, originally developed for Type 2 diabetes, could potentially help prevent chronic conditions in the long term. However, employers are faced with questions regarding who should have access to the costly drugs and how to ensure employees develop healthy habits to maximize the investment. Personify Health Chief Medical Officer Jeff Jacques discusses the different types of GLP-1 drugs, current employer adoption rates, and the potential for more employers to include them in their health benefit offerings in the future.
Source link
MedCity Pivot Podcast: Self-insured Employers Weigh Benefits of GLP-1 Drugs
